Anzeige
Mehr »
Donnerstag, 24.07.2025 - Börsentäglich über 12.000 News
Gamechanger im Anmarsch? Analysten sehen noch Nachholpotenzial bei dieser Aktie!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40QK8 | ISIN: US05330T2050 | Ticker-Symbol:
NASDAQ
23.07.25 | 21:59
1,415 US-Dollar
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
AUTONOMIX MEDICAL INC Chart 1 Jahr
5-Tage-Chart
AUTONOMIX MEDICAL INC 5-Tage-Chart

Aktuelle News zur AUTONOMIX MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAutonomix Medical, Inc. - 8-K, Current Report1
DiAutonomix Medical Announces exercise of warrants for $2.5M gross proceeds1
DiAutonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Proceeds2
MoAutonomix Medical: Aktie legt nach Erteilung von Patent für "Smart Torquer"-Technologie zu-
MoAutonomix Medical stock gains after securing smart torquer patent1
MoAutonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications105With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar...
► Artikel lesen
07.07.Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment1
AUTONOMIX MEDICAL Aktie jetzt für 0€ handeln
30.06.Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase ("PoC 2") of Proof-of-Concept Human Clinical Study128Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1...
► Artikel lesen
27.06.Autonomix erhält US-Patent für nervensensitive Medizintechnologie5
27.06.Autonomix receives US patent for nerve-sensing medical technology1
27.06.Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology388Patent supports the Company's broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity...
► Artikel lesen
05.06.Autonomix set to expand cancer pain treatment trial2
05.06.Autonomix erweitert klinische Studie zur Behandlung von Krebsschmerzen-
05.06.Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain4
29.05.Autonomix Medical, Inc. - 10-K, Annual Report2
22.05.AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech2
16.05.Autonomix picks up key nerve ablation catheter patent1
14.05.Autonomix Medical, Inc.: Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event1
13.05.Autonomix plans expansion phase for cancer pain trial2
13.05.Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market267Discussion in Virtual Investor CEO Connect focuses on Company's planned follow-on market expansion study phase ("PoC 2") of proof-of-concept trial; Access Here Additional indications potentially double...
► Artikel lesen
Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1